Skip to main content

Table 1 Characteristics of the patients with early RA and of the healthy controls included in the study

From: Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate

  RA patients Healthy controls
Number 19 17
Female, (%) 5 (26.3) 6 (35.3)
Age at diagnosis, median (IQR) 61.6 (51–65) 58 (39–64)
Symptoms to MTX, median months (IQR) 6.0 (2.2–7.3)  
RF (%) 11 (57.9)  
ACPA (%) 11 (57.9)  
Erosive arthritis (%) 2 (10.5)  
Smoking (%) 8 (42.1)  
Methylprednisolone, median mg/day (IQR) 4 (4–8)  
Metothrexate, median mg/week (IQR) 10 (10–10)  
CRP (mg/L), median (IQR)   
 Baseline 15.3 (3.9–23.2)  
 1 month 5.2 (1.2–9.4)  
ESR, median (IQR)   
 Baseline 28.0 (6.0–38.0)  
 1 month 14.0 (6.5–24.0)  
DAS28, mean ± SD   
 Baseline 4.6 ± 1.6  
 1 month 3.2 ± 1.5  
  1. RA rheumatoid arthritis, IQR interquartile range, MTX methotrexate, RF rheumatoid factor, ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity factor in 28 joints, SD standard deviation
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us